Aerocrine Acquires All Assets of U.S. Competitor, Apieron Inc. and Ends Litigation
Following Apieron’s launch in the U.S. of its Insight™ exhaled NO device in 2008, Aerocrine and Apieron have been engaged in patent litigation in the U.S and Germany. On March 30th 2010, referring to legal setbacks and lack of financing, Apieron filed for Chapter 7 bankruptcy. The bankruptcy court appointed a trustee to administer the liquidation of Apieron’s assets. In an auction held on May 12th in the United States Bankruptcy Court for the Northern District of California, Aerocrine acquired the rights to all of Apieron’s business assets, including its portfolio of patents and trademarks.
Due to small sales volumes and a manual process for the manufacturing of the Insight exhaled NO device, Aerocrine will not invest to resume supply of the Insight product that was discontinued by Apieron following its bankruptcy filing.
About Aerocrine Aerocrine AB is a medical technology company focused on the improved management and care of patients with inflammatory airway diseases. The pioneer and leader in the technology to monitor and manage airway inflammation, Aerocrine markets NIOX MINO® and NIOX® Flex. Both products enable the fast and reliable measurement of airway inflammation and may thus play a critical role in more effective diagnosis, treatment and follow-up of patients with inflammatory airway diseases such as asthma. Aerocrine is based in Sweden with subsidiaries in the US, Germany and the UK. Aerocrine shares were listed on the Stockholm Stock Exchange on June 15th 2007.
Aerocrine discloses the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 09:30 a.m. on May 19th 2010.
This information was brought to you by Cision http://www.cisionwire.com
Contact:
Aerocrine AB Paul de Potocki, CEO Telephone: +46 8 629 07 80 or Chip Neff, President Telephone: +1 919 696 4267